Preclinical pharmacology, pharmacokinetics, pharmacokinetic and early clinical research clearly shows that, as A new antiviral zanamivir, for the prevention and treatment of influenza A virus infection has the potential, according to the pharmacokinetic characteristics, zanamivir is suitable for every day, and it has good efficacy and safety.
Zanamivir, codenamed GG167 (former code GR - 121167 - x). Its CAS: 139110-80-8, is an effective flu virus sialic acid inhibitor, used for the prevention and treatment of influenza.
Zanamivir through inhibition of influenza virus neuraminidase, which changes the flu virus in the infected cells aggregation and release. In vitro experiment found that when the drug concentration increasing, there is still a flu virus sensitivity to zanamivir. Through analysis, it has to do with virus neuraminidase caused by mutation and blood agglutinin two or one amino acid change.
No comments:
Post a Comment